Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer

Phase 2 Terminated 6 enrolled Medical College of Wisconsin

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label study using pacritinib for patients with histologically confirmed prostate adenocarcinoma, status post definitive treatment and biochemical recurrence.

Timeline

Start: 2021-06-01
Primary completion: 2023-11-30
Completion: 2024-10-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pacritinib	Small molecule	200 mg	Oral

Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer

Summary

Timeline

Drugs

Indications